Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peanut Hypersensitivity | 4 | 2025 | 89 | 0.690 |
Why?
|
| Asthma, Aspirin-Induced | 1 | 2021 | 7 | 0.690 |
Why?
|
| Aspirin | 2 | 2021 | 216 | 0.650 |
Why?
|
| Cerebrovascular Trauma | 1 | 2020 | 4 | 0.640 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2020 | 3 | 0.640 |
Why?
|
| Head Injuries, Penetrating | 1 | 2020 | 8 | 0.640 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2020 | 64 | 0.610 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 302 | 0.590 |
Why?
|
| Arachis | 3 | 2025 | 76 | 0.580 |
Why?
|
| Aneurysm, False | 1 | 2020 | 84 | 0.580 |
Why?
|
| Agammaglobulinemia | 1 | 2018 | 43 | 0.580 |
Why?
|
| Desensitization, Immunologic | 4 | 2025 | 118 | 0.570 |
Why?
|
| Immunity, Humoral | 1 | 2018 | 76 | 0.560 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 223 | 0.530 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 572 | 0.520 |
Why?
|
| Neurosurgical Procedures | 1 | 2020 | 313 | 0.520 |
Why?
|
| Hydrocephalus | 1 | 2020 | 292 | 0.510 |
Why?
|
| Community-Acquired Infections | 1 | 2018 | 254 | 0.490 |
Why?
|
| Pneumonia | 1 | 2018 | 344 | 0.450 |
Why?
|
| Allergens | 4 | 2025 | 356 | 0.380 |
Why?
|
| Mass Screening | 1 | 2018 | 825 | 0.380 |
Why?
|
| Hypersensitivity | 2 | 2021 | 231 | 0.270 |
Why?
|
| Immunoglobulin G | 2 | 2021 | 810 | 0.260 |
Why?
|
| Telemedicine | 3 | 2021 | 518 | 0.230 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 366 | 0.220 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 377 | 0.220 |
Why?
|
| Infusions, Subcutaneous | 2 | 2021 | 7 | 0.210 |
Why?
|
| Pneumococcal Vaccines | 2 | 2021 | 176 | 0.180 |
Why?
|
| Nasal Polyps | 1 | 2020 | 28 | 0.170 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 49 | 0.160 |
Why?
|
| Remote Consultation | 1 | 2020 | 26 | 0.160 |
Why?
|
| Rhinitis | 1 | 2020 | 41 | 0.160 |
Why?
|
| Immune Tolerance | 1 | 2021 | 159 | 0.160 |
Why?
|
| Diphenhydramine | 1 | 2020 | 12 | 0.160 |
Why?
|
| Allergy and Immunology | 1 | 2020 | 31 | 0.160 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 179 | 0.160 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 458 | 0.160 |
Why?
|
| Nut Hypersensitivity | 1 | 2019 | 8 | 0.160 |
Why?
|
| Occupational Injuries | 1 | 2020 | 11 | 0.160 |
Why?
|
| Ventriculostomy | 1 | 2020 | 46 | 0.160 |
Why?
|
| Nuts | 1 | 2019 | 15 | 0.160 |
Why?
|
| Central Nervous System Cysts | 1 | 2019 | 12 | 0.150 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2021 | 210 | 0.150 |
Why?
|
| Cerebral Angiography | 1 | 2020 | 106 | 0.150 |
Why?
|
| Epidermal Cyst | 1 | 2019 | 17 | 0.150 |
Why?
|
| Craniopharyngioma | 1 | 2019 | 34 | 0.150 |
Why?
|
| Craniotomy | 1 | 2020 | 101 | 0.150 |
Why?
|
| Drug Hypersensitivity | 1 | 2020 | 97 | 0.150 |
Why?
|
| Dermoid Cyst | 1 | 2019 | 36 | 0.150 |
Why?
|
| Rituximab | 1 | 2020 | 174 | 0.150 |
Why?
|
| Epinephrine | 1 | 2020 | 150 | 0.150 |
Why?
|
| Pandemics | 3 | 2021 | 1159 | 0.140 |
Why?
|
| Pituitary Neoplasms | 1 | 2019 | 78 | 0.140 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 163 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 131 | 0.140 |
Why?
|
| Anaphylaxis | 1 | 2020 | 91 | 0.140 |
Why?
|
| Drainage | 1 | 2020 | 252 | 0.140 |
Why?
|
| Male | 11 | 2025 | 65107 | 0.130 |
Why?
|
| Administration, Oral | 3 | 2025 | 705 | 0.130 |
Why?
|
| Humans | 16 | 2025 | 131403 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2021 | 6481 | 0.110 |
Why?
|
| Adult | 5 | 2021 | 31625 | 0.100 |
Why?
|
| Female | 10 | 2025 | 71028 | 0.100 |
Why?
|
| Length of Stay | 1 | 2018 | 1393 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2114 | 0.090 |
Why?
|
| Telephone | 2 | 2021 | 115 | 0.080 |
Why?
|
| Time Factors | 1 | 2020 | 6273 | 0.080 |
Why?
|
| Aged | 4 | 2021 | 21213 | 0.070 |
Why?
|
| Betacoronavirus | 2 | 2020 | 287 | 0.060 |
Why?
|
| Age Factors | 2 | 2025 | 2869 | 0.060 |
Why?
|
| Risk Factors | 1 | 2018 | 10946 | 0.050 |
Why?
|
| Infant | 3 | 2025 | 13292 | 0.050 |
Why?
|
| Middle Aged | 5 | 2021 | 28804 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2025 | 15037 | 0.050 |
Why?
|
| Diphtheria Toxoid | 1 | 2021 | 6 | 0.050 |
Why?
|
| Diphtheria | 1 | 2021 | 17 | 0.040 |
Why?
|
| Tetanus Toxoid | 1 | 2021 | 48 | 0.040 |
Why?
|
| Tetanus | 1 | 2021 | 22 | 0.040 |
Why?
|
| Serogroup | 1 | 2021 | 67 | 0.040 |
Why?
|
| Electronics | 1 | 2020 | 45 | 0.040 |
Why?
|
| Mouthwashes | 1 | 2020 | 10 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 741 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 44 | 0.040 |
Why?
|
| Office Visits | 1 | 2020 | 81 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2020 | 132 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 313 | 0.040 |
Why?
|
| Skin Tests | 1 | 2019 | 100 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2021 | 389 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 513 | 0.040 |
Why?
|
| Immunoglobulin E | 1 | 2019 | 225 | 0.040 |
Why?
|
| Outpatients | 1 | 2020 | 266 | 0.040 |
Why?
|
| Adenoma | 1 | 2019 | 145 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 310 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2020 | 565 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 562 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2022 | 765 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1231 | 0.030 |
Why?
|
| Inpatients | 1 | 2020 | 545 | 0.030 |
Why?
|
| Young Adult | 2 | 2020 | 10081 | 0.030 |
Why?
|
| Child | 3 | 2020 | 26223 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1589 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2020 | 809 | 0.020 |
Why?
|
| Adolescent | 2 | 2020 | 20900 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3833 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 2105 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 6911 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2025 | 12921 | 0.020 |
Why?
|